IOL Chemicals & Pharmaceuticals delivered a strong start to fiscal year 2027, reporting a 90% year-on-year rise in net profit to ₹64.5 crore for the quarter ended June 30, 2026. The surge in profitability was underpinned by higher operating leverage, improved capacity utilization, and a favorable shift in product mix, particularly within its pharmaceutical division.

Revenue from operations expanded by 37% to ₹756 crore, up from ₹551 crore in the corresponding quarter of the previous fiscal year. Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 60.7% to ₹111 crore, reflecting robust operational efficiencies across both its chemical and pharmaceutical segments.

Financial Performance Overview

The company’s financial metrics for Q1 FY27 highlight significant improvement in both top-line growth and margin expansion compared to Q1 FY26.

Net profit margin improved to 8.4%, up from 6.1% in the prior year period. Management attributed the bottom-line growth to internal efficiencies rather than one-time inventory gains, despite earlier market volatility affecting raw material prices.

What the Numbers Show

A key structural shift is evident in the pharmaceutical division, where non-ibuprofen products now contribute 43% of pharma revenue, up from 36% in Q1 FY26. This segment grew by 67% year-on-year, emerging as a primary growth driver. This diversification reduces reliance on ibuprofen and aligns with the company’s strategy to build an integrated API platform with multiple revenue streams.

Export contribution also strengthened, rising to 28.5% of total revenue from 24.4% in the previous year. This expansion into international markets, supported by regulatory approvals such as NMPA clearance for clopidogrel in China, indicates growing competitiveness in regulated overseas markets.

Segment Insights and Guidance

In the chemical business, improved realizations and efficient raw material procurement supported performance. Capacity enhancements across key product lines provided greater flexibility to meet demand. For the full fiscal year 2027, management guided for 15% to 20% revenue growth and an EBITDA margin range of 14% to 15%.

Looking ahead to FY28, the company anticipates sustaining this momentum with a target revenue growth of 15% to 20% and EBITDA margins potentially reaching 15% to 17%, contingent on current market scenarios remaining stable. Capital expenditure remains disciplined at approximately ₹200 crore annually, with 60% directed toward expansion and new products.

IOL Chemicals & Pharmaceuticals IOL Chemicals & Pharmaceuticals delivered strong financial performance in the first quarter of FY27, reporting significant growth across key profitability metrics. The company’s standalone profit before tax (PBT) surged 90.5% year-on-year to ₹86.8 crore, up from ₹45.5 crore in Q1FY26. Net profit after tax followed suit, rising 89.9% to ₹64.5 crore from ₹34.0 crore in the corresponding previous period.

Revenue from operations grew by 37.1% to ₹756.3 crore in Q1FY27, compared to ₹551.7 crore in Q1FY26. This top-line expansion was accompanied by improved operational efficiency, with EBITDA jumping 60.7% to ₹111.7 crore. Consequently, the EBITDA margin expanded by 220 basis points to 14.6% from 12.4% in the prior year quarter. Earnings before interest and taxes (EBIT) also rose sharply by 81.7% to ₹90.4 crore.

Segmental and Geographical Performance

The pharmaceutical segment continued to be the primary revenue driver, generating ₹469.5 crore in Q1FY27, up from ₹374.5 crore in Q1FY26. This represents a 25.4% year-on-year growth for the pharma business. The chemicals segment, net of intersegment transfers, contributed ₹286.8 crore, marking a substantial recovery from ₹244.9 crore in Q1FY26.

Geographically, the company remains heavily reliant on international markets. Exports accounted for 71% of total revenue, while domestic sales constituted the remaining 29%. This export-oriented structure highlights the company’s integration into global supply chains, particularly for active pharmaceutical ingredients (APIs) and specialty chemicals.

What the Numbers Show

A notable divergence exists between revenue growth and cost management in Q1FY27. While revenue grew 37.1%, employee benefits expense increased by only 23.4% (from ₹57.7 crore to ₹71.2 crore). Similarly, finance costs declined slightly to ₹3.6 crore from ₹4.2 crore in the prior year period. This suggests improved operating leverage, where fixed costs are being spread over a larger revenue base, directly contributing to the margin expansion observed in EBITDA and PAT percentages.

Balance Sheet and Cash Flow Position

As of March 2026, the company maintained a healthy balance sheet with total equity standing at ₹1,798.4 crore. Total borrowings under current liabilities were ₹132.0 crore, while non-current financial liabilities remained negligible at zero. Cash and cash equivalents at the end of FY26 stood at ₹65.3 crore, down from ₹78.0 crore at the end of FY25, reflecting ongoing capital investments and working capital requirements.

Operating cash flows remained robust, with net cash from operating activities totaling ₹214.4 crore in FY26, compared to ₹178.7 crore in FY25. This strong cash generation supports the company’s expansion plans, including the recently acquired 101-acre land parcel near Chandigarh-Bathinda Highway for future manufacturing capacity.

Strategic Outlook

The company continues to diversify beyond its core Ibuprofen business. The non-Ibuprofen share in the pharmaceuticals segment has grown from 18% to 37% over the past six years. Key products driving this diversification include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole. With 14 DMFs filed with the USFDA and 21 CEPs with EDQM, IOL Chemicals is positioned to expand its footprint in regulated markets.

The investor presentation, submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary, on August 12, 2026.